{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:04:14Z","timestamp":1791230654554,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue. Preclinical studies suggest that iodine-131 (<jats:sup>131<\/jats:sup>I) \u2013TM-601 may be an effective targeted therapy for the treatment of glioma. We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered <jats:sup>131<\/jats:sup>I-TM-601 in patients with recurrent glioma. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of \u2265 60% who were eligible for cytoreductive craniotomy were enrolled. An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery. Two weeks after surgery, patients received a single dose of <jats:sup>131<\/jats:sup>I-TM-601 from one of three dosing panels (0.25, 0.50, or 1.0 mg of TM-601), each labeled with 10 mCi of <jats:sup>131<\/jats:sup>I. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Intracavitary administration was well tolerated, with no dose-limiting toxicities observed. <jats:sup>131<\/jats:sup>I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system. Nonbound peptide was eliminated from the body within 24 to 48 hours. Only minor adverse events were reported during the 22 days after administration. At day 180, four patients had radiographic stable disease, and one had a partial response. Two of these patients further improved and were without evidence of disease for more than 30 months. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> A single dose of 10 mCi <jats:sup>131<\/jats:sup>I-TM-601 was well tolerated for 0.25 to 1.0 mg TM-601 and may have an antitumoral effect. Dosimetry and biodistribution from this first trial suggest that phase II studies of <jats:sup>131<\/jats:sup>I-TM-601 are indicated. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.05.4569","type":"journal-article","created":{"date-parts":[[2006,7,28]],"date-time":"2006-07-28T23:30:31Z","timestamp":1154129431000},"page":"3644-3650","source":"Crossref","is-referenced-by-count":193,"title":["Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma"],"prefix":"10.1200","volume":"24","author":[{"given":"Adam N.","family":"Mamelak","sequence":"first","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bucholz","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Raubitschek","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Burt","family":"Nabors","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Fiveash","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui","family":"Shen","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Khazaeli","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Colcher","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Osman","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Guthrie","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Schade-Bijur","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Hablitz","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon L.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Gonda","sequence":"additional","affiliation":[{"name":"From the Cedars Sinai Medical Center, Los Angeles; City of Hope Cancer Center, Duarte, CA; University of Alabama at Birmingham; TransMolecular Inc, Birmingham, AL; and Saint Louis University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08091-1"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.07.005"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200305000-00003"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1993.264.2.C361"},{"key":"R7","unstructured":"Soroceanu L, Gillespie Y, Khazaeli MB, et al: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 58:4871,1998-4879,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-0890-4"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.171"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1210932"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L"},{"key":"R12","unstructured":"Hockaday DC, Shen S, Fiveash J, et al: Imaging glioma extent with I-TM-601. J Nucl Med 46:580,2005-586, 131"},{"key":"R13","unstructured":"Shen S, Forero A, LoBuglio AF, et al: Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 46:642,2005-651,"},{"key":"R14","unstructured":"Sabin MG: MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538,1996-546,"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1988.68.5.0698"},{"key":"R16","unstructured":"Harsh GR: Management of recurrent gliomas, in Berger MS, Wilson CB (eds): The Gliomas . Philadelphia, PA, WB Saunders, p 649,1999"},{"key":"R17","unstructured":"Sgouros G: Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34:689,1993-694,"},{"key":"R18","unstructured":"Shen S, DeNardo GL, Sgouros G, et al: Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 40:2102,1999-2106,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1002\/glia.10083"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"R21","unstructured":"Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693,2002-713,"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2005.02.006"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02152.x"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020805"},{"key":"R25","unstructured":"Akabani G, Reardon DA, Coleman RE, et al: Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant glioma: A phase II study. J Nucl Med 46:1042,2005-1051,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(04)01305-7"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000620"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.05.4569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:23:48Z","timestamp":1653513828000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.05.4569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":25,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2006,8,1]]}},"alternative-id":["10.1200\/JCO.2005.05.4569"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.05.4569","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}